Is Tazemetostat already on the market in China and its launch time?

Tazemetostat is the world's first EZH2 inhibitor, mainly used to treat patients with relapsed or refractory follicular lymphoma (FL). The drug was developed by Epizyme, and Chi-Med is responsible for its research, development and commercialization in mainland China. On March 18, 2025, tazetostat was approved by the China State Medical Products Administration ( NMPA) has been approved for marketing for the treatment of adult patients with EZH2 mutation-positive relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. This approval marks the official entry of tazerestat into the Chinese market.

After being launched in China, Chi-Med held the first nationwide commercial shipment ceremony of tazerestat on July 8, 2025, marking the official launch of the drug into clinical use. Medicines have been shipped from Shanghai’s innovative drug production base to pharmacies across the country for patients to use.

Regarding price, since tazerestat has just been launched in the Chinese market, the specific price has not yet been made public. Patients can consult their local hospital pharmacy for the latest information. In foreign countries, the price of original drugs is relatively high, and the American and Japanese versions can cost up to 10,000 to 20,000 yuan. However, the price of generic drugs produced in Laos is relatively low, about more than 4,000 yuan, and their ingredients are basically the same as the original drugs.

Overall, the launch of tazerestat in the Chinese market provides a new treatment option for patients with relapsed or refractory follicular lymphoma. As the market develops further, patients can obtain more information about drug prices and reimbursement by consulting their hospital pharmacies.

Reference materials:https://www.drugs.com/